Argen-x baanbrekend !
Leukemie / bloedkanker / MG spierziektes etc
Dive Brief: On Monday, argenx' stock price hit an all-time high of $43.25 when the company released data for its antibody targeting CD70, cusatuzumab (ARGX-110), and topline results of the lead drug efgartigimod (ARGX-113) in autoimmune disease myasthenia gravis. Off the back of the positive data, the biotech launched a follow-on public offering. The current offering is of $150 million of American depositary shares at a nominal value of €0.10 (around $0.12) per share. The stock bump came from the positive results of efgartigimod, which had a statistically significant benefit at six weeks compared with placebo, with 75% of patients showing a clinically meaningful benefit.
Dive Insight: The biotech focuses on antibody-based therapies in autoimmune disease and cancer, closed its initial public offering in May 2017, raising around $114.7 million, making it one of a rash of companies to go public in the first half of the year. While the company's business strategy is to seek strategic partnerships for risk-sharing and out-licensing deals, this cash injection is likely to be useful for a company with three wholly-owned products in multiple clinical trials. Efgartigimod (ARGX-113), argenx' lead candidate, is in three Phase 2 trials, including immune thrombocytopenia and pemphigus vulgaris. ? Topline results of Phase 1/2 trials of the lead drug efgartigimod (ARGX-113), an antibody fragment, showed a favorable safety profile, and a strong clinical improvement over placebo in patients with the autoimmune disease myasthenia gravis. These will be presented in full at the American Academy of Neurology annual meeting next April. Cusatuzumab (ARGX-110) is a little earlier in development, with Phase 1/2 trials ongoing in T-cell lymphoma, and acute myeloid leukemia. In AML, the data suggests, according to argenx, that the drug could be active both at the circulating and bone marrow blast levels and at the leukemic stem cell, supporting its potential activity in the disease. In Phase 1/2 clinical trial in acute myeloid leukemia presented at the American Society of Hematology meeting, the first six patients showed positive signs of clinical activity, with three in complete remission.
In an update on the Phase 2 part of its clinical trial with cusatuzumab in cutaneous T-cell lymphoma, of 22 patients, there was one complete response, two partial responses and ten patients with stable disease.
Wat denken jullie dat alleen al de markt voor behandeling Leukemie (bloedkanker ) zal zijn ? Hebben we het nog niet over het baanbrekende nieuws mbt spierziekte MG ( waar nog helemaal niets voor is op de markt en de ARGNX113 molecule . En dan nog de complete rest van de pipeline .
Begrijpen jullie nu waarom de koers zo hard omhoog is gegaan / gaat . Dit is baanbrekend wereld nieuws toch .